期刊文献+

Allogeneic Immunotherapy for Relapsed Multiple Myeloma:Role of Matched Unrelated Donors

复发多发性骨髓瘤的异基因免疫疗法:匹配的非亲属供者的作用(英文)
下载PDF
导出
摘要 Summary Existence of a graft-versus-myeloma effect has been well documented by responses to donor lymphocyte infusions and long-term survival after allogeneic bone marrow transplantation. The development of non-myeloablative conditioning regimens allows utilization of allogeneic effects in patients usually not suitable for myeloablative allogeneic transplantation, such as older and heavily pretreated patients. In a small series of 11 patients with multiple myeloma relapsing after autologous transplantation, we show that conditioning with low-dose total body irradiation in combination with fludarabine allows stable engraftment after matched unrelated donor transplantation and is tolerated with acceptable transplant-related morbidity and mortality. With a short median follow-up of 225 days, disease control was achieved only for patients responding to conventional treatment prior to allografting. Future studies with longer follow-up have to define the role of non-myeloablative allogeneic transplantation from unrelated donors as consolidation for patients responding to salvage therapy.
出处 《The Chinese-German Journal of Clinical Oncology》 CAS 2002年第2期72-74,共3页 中德临床肿瘤学杂志(英文版)
关键词 relapsed multiple myeloma allogeneic immonotherapy donor 复发多发性骨髓瘤 异基因免疫疗法 非亲属供体 治疗
  • 相关文献

参考文献15

  • 1BacharLustig E, Rachamim N, LiHW, et al. Megadose of T cel ldepleted bone marrow overcomes MHC barriers insubletbally irradiated mice. N at Med, 1995,1(12):1268-1273.
  • 2Bensinger WI, Buckner CD, Anasetti C,et al. Allogeneic marrow transpl antation formultip le mycloma:an analysis of risk factors on outcome. Blood, 1996,88(7):2787-2793. 
  • 3Bjorkstrand BB, Ljungman P, Svensson H, et al. Allogeneic bone marrowtransplantation versu s autologous stem cell transplantation in multiple myeloma: aretrospective casc matched study from the European Group for Blood and MarrowTransplantation. Bl ood, 1996,88(12):4711-4718.
  • 4Fuchimoto Y, Huang CA, Yamada K, et al. Mixed chimcrism and tolerance without wholebody irradiation in a large animal model. J Clin Invest,2000,105(12):1779-1789. 
  • 5Gahrton G, Tura S, Ljungman P,et al. An update of prognostic factors for allogeneicbo ne marrow transplantation in multiple myeloma using matched sibling donors. Euro peanGroup for Blood and Marrow Transplantation. Stem Cells, 1995,13 Suppl 2:1 22-125.
  • 6Garban F, Attal M, Rossi JF, et al. Immunotherapy by nonmyeloablati veallogeneic ste m cell transplantation in multiple mycloma:results of a pilot study assalvage t herapy after autologous transplantation. Leukemia, 2001,15(4):642-646.
  • 7Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hemato poieticprogenitor cells with purine analogcontaining chemotherapy: harnessing graftversusleukemia without myeloablative therapy. Blood, 1997,89(12):4531-4536.
  • 8Giralt S, Khouri I, Champlin R. Non myeloablative "mini transplants" .Cancer Treat Res, 1999,101:97-108.
  • 9Goerner M, et al. Allogeneic transplantation after lymphoablative co nditioning inmultiple myeloma. Bone Marrow Transplant, 2001, 27 Suppl 2:247.
  • 10Porter DL, Luger SM, Duffy KM, et al. Allogeneic cell therapy for pa tients whorelapse a fter autologous stem ccll transplantation. Biol Blood Marrow Transplant, 2001,7(4):230-238.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部